Trial Profile

A clinical trial of Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tc 99m tilmanocept (Primary)
Indications Malignant melanoma; Mouth neoplasm
Focus Diagnostic use

Most Recent Events

08 Aug 2022 New trial record
01 Aug 2022 According to a Navidea Biopharmaceuticals media release, this study was led by Principal Investigator Dr. Muzib Abdul-Razak
01 Aug 2022 According to a Navidea Biopharmaceuticals media release, data published in the ANZ Journal of Surgery.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com